Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

9.480 +0.070 (+0.74%)
Official Closing Price Updated: 4:10 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why Biohaven Stock Dove by Nearly 20% on Thursday ↗
Via The Motley Fool
News headline image
Why Is Biohaven Stock Falling On Thursday? ↗
Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations. 
Via Benzinga
News headline image
Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug ↗
The company hadn't expected an advisory committee meeting, nor a three-month pushback for its rare-disease drug review. 
Via Investor's Business Daily
News headline image
Why Biohaven Stock Triumphed on Tuesday ↗
Via The Motley Fool
News headline image
What's Going On With Merus Stock Monday? ↗
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
News headline image
Red Cat Holdings, Alibaba, DXC Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BioHaven Stock Is Soaring Today ↗
Via The Motley Fool
Topics Stocks
News headline image
Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland ↗
Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves expected to reach $489 million. 
Via Benzinga
News headline image
Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Why Biohaven Stock Plummeted by More Than 15% Today ↗
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗
Via The Motley Fool
Topics Bankruptcy Economy World Trade
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity ↗
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
Via Investor's Business Daily
News headline image
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy ↗
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile. 
Via Benzinga
News headline image
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
News headline image
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines ↗
The company could soon add a new, high-value treatment to its portfolio. 
Via Investor's Business Daily
News headline image
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force ↗
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory... 
Via Benzinga
Topics Regulatory Compliance
News headline image
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval ↗
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.